Senolytics in early human trials: what dasatinib plus quercetin and fisetin actually showed, and the senescence-marker problem

The biology, briefly

Cellular senescence is a state in which cells stop dividing but remain metabolically active and can secrete a pro-inflammatory profile (the senescence-associated secretory phenotype, or SASP). Senescent cells accumulate with age in many tissues. The senolytic hypothesis is that selectively clearing these cells will reduce age-related dysfunction. Animal data are striking; the human translation is still being built.

Dasatinib plus quercetin: what early human trials measured

• Open-label pilot studies in idiopathic pulmonary fibrosis showed signals of improved physical function over weeks of intermittent dosing .
• Small trials in diabetic kidney disease reported reductions in tissue senescent-cell burden assessed via biopsy markers.
• Trial designs use intermittent dosing (a few days at a time, every few weeks) rather than continuous dosing, consistent with the hit-and-run model from animal work.
• Sample sizes are small (typically 5 to 30 patients), endpoints vary across trials, and most reports come from a small set of research groups.

Fisetin and other candidates

Fisetin is a plant flavonoid with senolytic activity in screening assays. ClinicalTrials.gov lists multiple registered fisetin trials, including studies in osteoarthritis and post-acute COVID-19 . Other candidates (navitoclax-derived compounds, FOXO4-DRI, certain HSP90 inhibitors) are mostly preclinical or in earliest human studies.

The senescence measurement problem

There is no single blood test for senescent-cell burden in humans. Tissue biopsy is the most direct method but is invasive and tissue-specific. Circulating SASP proteins (IL-6, GDF15, MMP-3, others) are noisy and overlap with general inflammation. Newer multi-omic biomarker panels are being developed but are not standardized . This matters because trials cannot easily measure their own pharmacodynamic effect.

Safety and clinical context

Dasatinib is an FDA-approved tyrosine-kinase inhibitor for chronic myeloid leukemia, with a label that includes hematologic, cardiac, and pulmonary precautions . Off-label use in healthy adults for senolytic purposes is not the same risk profile as oncology use, but the side-effect profile is also not benign. Quercetin and fisetin are sold as supplements; their drug-interaction profiles deserve attention even though they have lower acute toxicity in registered trials.